Status:

COMPLETED

A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Metabolism and Nutrition Disorder

Obesity

Eligibility:

All Genders

22-55 years

Phase:

PHASE1

Brief Summary

This study looks at a new study medicine for weight control in people with overweight or obesity. The aim of this study is to see if the study medicine is safe for people to take. The study also looks...

Eligibility Criteria

Inclusion

  • Male aged 22-55 years (both inclusive) or female aged 22-45 years (both inclusive) at the time of signing informed consent
  • Female must have regular menstrual cycle(defined as 24-35 days between 1st day of menses for two most recent menstrual periods, self-reported)
  • Female must have bilateral tubal ligation or must be willing to use non-hormonal intrauterine device or diaphragm /cervical cap with spermicide in combination with condom for male partner(s)
  • Body mass index (BMI) between 27.0 and 39.9 kg/sqm (both inclusive). Overweight should be due to excess adipose tissue, as judged by the investigator
  • Considered by the investigator to be generally healthy based on the medical history, physical examination, and the results of vital signs, ECG, and clinical laboratory tests performed during the screening visit

Exclusion

  • Any disorder, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol
  • Use of prescription or non-prescription medicinal products including herbal products and non-routine vitamins, within 2 weeks prior to screening. Mild painkillers are allowed until 24 hours prior to screening
  • History or presence of bone disease or otherwise increased risk of bone fracture as evaluated by dual-energy x-ray absorptiometry and as judged by the investigator

Key Trial Info

Start Date :

March 13 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 4 2019

Estimated Enrollment :

57 Patients enrolled

Trial Details

Trial ID

NCT03479892

Start Date

March 13 2018

End Date

June 4 2019

Last Update

June 26 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Novo Nordisk Investigational Site

San Antonio, Texas, United States, 78209